GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » Net Change in Cash

Argent Biopharma (LSE:RGT) Net Change in Cash : £0.29 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Argent Biopharma's Net Change in Cash for the six months ended in Jun. 2024 was £-3.02 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was £0.29 Mil.

Argent Biopharma Net Change in Cash Historical Data

The historical data trend for Argent Biopharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Net Change in Cash Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 1.94 -2.02 -0.87 0.24

Argent Biopharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.53 -0.42 -0.48 3.30 -3.02

Argent Biopharma Net Change in Cash Calculation

Argent Biopharma's Net Change in Cash for the fiscal year that ended in Jun. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-7.444+-0.073+7.758+-0.001
=0.24

Argent Biopharma's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.317+-0.064+0.368+-0.003
=-3.02

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » Net Change in Cash
Comparable Companies
ASX:AGH ASX:IVX ASX:EOF ASX:CAN ASX:ECS ASX:EXL ASX:BP8 ASX:ME1 ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
RGTLF:USA H5O0:Germany RGT:Australia
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.